Trial Profile
A Multicenter Phase 2 Study of Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) in Recurrent WHO Grade IV Malignant Glioma Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Oct 2023
Price :
$35
*
At a glance
- Drugs Lerapolturev (Primary)
- Indications Glioma
- Focus Therapeutic Use
- Sponsors Istari Oncology
- 26 Sep 2023 Planned End Date changed from 1 Dec 2023 to 1 Mar 2024.
- 26 Sep 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Mar 2024.
- 16 Jun 2020 Status changed from recruiting to active, no longer recruiting.